Parkman Healthcare Partners LLC Takes Position in Vera Therapeutics, Inc. $VERA

Parkman Healthcare Partners LLC bought a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) in the 1st quarter, Holdings Channel reports. The firm bought 76,125 shares of the company’s stock, valued at approximately $1,829,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its position in shares of Vera Therapeutics by 8.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,754,832 shares of the company’s stock valued at $114,212,000 after acquiring an additional 377,783 shares in the last quarter. Vestal Point Capital LP increased its position in shares of Vera Therapeutics by 132.6% during the first quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company’s stock valued at $60,050,000 after acquiring an additional 1,425,000 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its position in shares of Vera Therapeutics by 18.4% during the first quarter. T. Rowe Price Investment Management Inc. now owns 1,675,367 shares of the company’s stock valued at $40,243,000 after acquiring an additional 260,188 shares in the last quarter. Paradigm Biocapital Advisors LP increased its position in shares of Vera Therapeutics by 31.0% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,437,339 shares of the company’s stock valued at $60,785,000 after acquiring an additional 340,488 shares in the last quarter. Finally, Woodline Partners LP increased its position in shares of Vera Therapeutics by 20.1% during the fourth quarter. Woodline Partners LP now owns 1,202,466 shares of the company’s stock valued at $50,852,000 after acquiring an additional 201,573 shares in the last quarter. Institutional investors own 99.21% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on VERA shares. HC Wainwright reissued a “buy” rating and set a $85.00 price target (up previously from $75.00) on shares of Vera Therapeutics in a research report on Monday, June 2nd. JPMorgan Chase & Co. reduced their price target on shares of Vera Therapeutics from $56.00 to $53.00 and set an “overweight” rating for the company in a research report on Thursday, August 7th. Wolfe Research reaffirmed a “peer perform” rating on shares of Vera Therapeutics in a research report on Monday, August 4th. Guggenheim reaffirmed a “buy” rating on shares of Vera Therapeutics in a research report on Tuesday, June 3rd. Finally, Scotiabank reaffirmed an “outperform” rating on shares of Vera Therapeutics in a research report on Tuesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Vera Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $63.00.

Insider Buying and Selling at Vera Therapeutics

In related news, Director Patrick G. Enright purchased 209,393 shares of the firm’s stock in a transaction on Monday, June 23rd. The shares were acquired at an average price of $20.87 per share, for a total transaction of $4,370,031.91. Following the purchase, the director directly owned 3,569,522 shares in the company, valued at $74,495,924.14. This trade represents a 6.23% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 16.30% of the company’s stock.

Vera Therapeutics Trading Up 10.5%

NASDAQ:VERA opened at $24.19 on Friday. The company has a current ratio of 17.03, a quick ratio of 17.03 and a debt-to-equity ratio of 0.16. Vera Therapeutics, Inc. has a 12 month low of $18.53 and a 12 month high of $51.61. The company has a market cap of $1.54 billion, a PE ratio of -6.76 and a beta of 1.17. The company has a 50 day simple moving average of $22.19 and a two-hundred day simple moving average of $23.39.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.38). During the same quarter in the previous year, the company earned ($0.62) EPS. Research analysts forecast that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.